RBD5044
Phase 2Small molecule
RBD5044 is one of 15 small molecule programs targeting Hypertriglyceridemia. It is currently in Phase 2.
1
Indications
3
Total Trials
2
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
17 competitors in Hypertriglyceridemia
#DrugCompanyPhaseTrials
1Cipro
BayerApproved
Crestor
AstraZenecaApproved
Selzentry
GSKApproved
Lopid
PfizerApproved
Zocor
OOrganon and Co
Approved
Topamax
WWim Janssens
Approved
Tryngolza (autoinjector)
Ionis PharmaceuticalsPhase 3
Redemplo
Arrowhead PharmaceuticalsPhase 3
Avandia
Jazz PharmaceuticalsPreclinical
Repatha
AmgenPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Tics1 trial
Dyslipidemias1 trial
Hypertriglyceridemia1 trial
A Multi-center, Randomized, Double-Blind, Placebo-Controlled Phase II Trial Evaluating the Efficacy and Safety of RBD5044 in Chinese Participants With Hypertriglyceridemia
Active, not recruiting·RRibotek Biopharmaceuticals (Shandong) Co., Ltd·Phase 2·NCT07587788·40 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RBD5044. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- RRibocure Pharmaceuticals AB